Raymond James analyst Steven Seedhouse downgraded CymaBay Therapeutics (CBAY) to Market Perform from Strong Buy without a price target following the announcement of its proposed acquisition by Gilead (GILD) for $32.50 per share.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on CBAY:
- M & A News: Gilead (NASDAQ:GILD) to Acquire CymaBay
- CymaBay Therapeutics’ Strategic Merger with Gilead Sciences
- CymaBay Therapeutics to Participate in Upcoming Investment Conferences
- CymaBay price target raised to $26 from $22 at Oppenheimer
- CymaBay Therapeutics Boosts Director Equity, Announces Officer Changes